205. 脆弱X症候群関連疾患 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 5) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 25
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
Allopregnanolone
Randi J. Hagerman, MD
2015 Phase 2 NCT02603926 United States;
Citocoline
Rush University Medical Center
2015 Phase 2 NCT02197104 United States;
Cyclophosphamide
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Magnetic resonance imaging
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Memantine
University of California, Davis
2007 - NCT00584948 United States;
Prednisone
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Sulforaphane
University of California, Davis
2021 - NCT05233579 United States;
Therapeutic immune globulin
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Randi J. Hagerman, MD
2015 Phase 2 NCT02603926 United States;
Citocoline
Rush University Medical Center
2015 Phase 2 NCT02197104 United States;
Cyclophosphamide
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Magnetic resonance imaging
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Memantine
University of California, Davis
2007 - NCT00584948 United States;
Prednisone
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;
Sulforaphane
University of California, Davis
2021 - NCT05233579 United States;
Therapeutic immune globulin
Children's Oncology Group
2004 Phase 3 NCT00033293 Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States;